Search hospitals

>

Minnesota

>

Minneapolis

Minneapolis VA Health Care System, Minneapolis, MN

Claim this profile

Minneapolis, Minnesota 55417

Global Leader in Lung Cancer

Global Leader in Post-Traumatic Stress Disorder

Conducts research for Prostate Cancer

Conducts research for Colorectal Cancer

Conducts research for Leukemia

391 reported clinical trials

30 medical researchers

Photo of Minneapolis VA Health Care System, Minneapolis, MN in MinneapolisPhoto of Minneapolis VA Health Care System, Minneapolis, MN in MinneapolisPhoto of Minneapolis VA Health Care System, Minneapolis, MN in Minneapolis

Summary

Minneapolis VA Health Care System, Minneapolis, MN is a medical facility located in Minneapolis, Minnesota. This center is recognized for care of Lung Cancer, Post-Traumatic Stress Disorder, Prostate Cancer, Colorectal Cancer, Leukemia and other specialties. Minneapolis VA Health Care System, Minneapolis, MN is involved with conducting 391 clinical trials across 425 conditions. There are 30 research doctors associated with this hospital, such as Santiago Garcia, MD, Mark A. Klein, Sharon D. Luikart, and Kelvin Lim, MD.

Area of expertise

1

Lung Cancer

Global Leader

Minneapolis VA Health Care System, Minneapolis, MN has run 42 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage II
Stage III
2

Post-Traumatic Stress Disorder

Global Leader

Minneapolis VA Health Care System, Minneapolis, MN has run 35 trials for Post-Traumatic Stress Disorder.

Top PIs

Clinical Trials running at Minneapolis VA Health Care System, Minneapolis, MN

Lung Cancer

Post-Traumatic Stress Disorder

Prostate Cancer

Cancer

Non-Small Cell Lung Cancer

Parkinson's Disease

Bipolar Disorder

Heart Failure

Chronic Obstructive Pulmonary Disease

Obesity

Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Recruiting

2 awards

Phase 3

27 criteria

Image of trial facility.

Ceralasertib + Durvalumab

for Non-Small Cell Lung Cancer

This phase III trial compares the effect of adding AZD6738 to durvalumab versus durvalumab alone to increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery. AZD6738 may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Adding AZD6738 to durvalumab may increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery.

Recruiting

2 awards

Phase 3

10 criteria

Image of trial facility.

Durvalumab

for Lung Cancer

This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The usual approach for patients who are not in a study is to closely watch a patient's condition after surgery and to have regular visits with their doctor to watch for signs of the cancer coming back. Usually, patients do not receive further treatment unless the cancer returns. This study will help determine whether this different approach with durvalumab is better, the same, or worse than the usual approach of observation. Giving durvalumab may help patients live longer and prevent early-stage non-small cell lung cancer from coming back as compared to the usual approach.

Recruiting

2 awards

Phase 3

8 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Minneapolis VA Health Care System, Minneapolis, MN?

Where is Minneapolis VA Health Care System, Minneapolis, MN located?

Who should I call to ask about financial aid or insurance network?

What insurance does Minneapolis VA Health Care System, Minneapolis, MN accept?

What awards or recognition has Minneapolis VA Health Care System, Minneapolis, MN received?